Navigation Links
Clarient Completes Second Tranche of Private Placement of Convertible Preferred Stock With Oak Investment Partners
Date:5/18/2009

Clarient combines innovative diagnostic technologies with world class pathology expertise to assess and characterize cancer. Clarient's mission is to become the leader in cancer diagnostics by dedicating itself to collaborative relationships with the healthcare community to translate cancer discovery and research into better patient care. The Company's principal customers include pathologists, oncologists, hospitals and biopharmaceutical companies. The rise of individualized medicine as the new direction in oncology has created the need for a centralized resource providing leading diagnostic technologies, such as flow cytometry and molecular testing. Clarient is that resource, having created a state-of-the-art commercial cancer laboratory providing the most advanced oncology testing and diagnostic services available both onsite and over the web. The Company is also developing new, proprietary "companion" diagnostic markers for therapeutics in breast, prostate, lung and colon cancers, and leukemia/lymphoma. Clarient is a Safeguard Scientifics, Inc. partner company. www.clarientinc.com

About Oak Investment Partners

Oak Investment Partners is a multi-stage venture capital firm with a total of $8.4 billion in committed capital. The primary investment focus is on high growth opportunities in Healthcare Information and Services, Information Technology and Software Outsourced Services, Consumer Internet/New Media, Financial Services Technology, Clean Energy, Broadband Internet and Wireless Communications, and Retail. Over a 30-year history, Oak has achieved a strong track record as a stage-independent investor funding more than 481 companies at key points in their lifecycles. Oak has been involved in the formation of companies, funded spinouts of operating divisions and technology assets, and provided growth equity to mid- and late-stage private businesses
'/>"/>

SOURCE Clarient, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Clarient Granted Exclusive License to Commercialize Breast Cancer Biomarker by Indiana University Research and Technology Corporation
2. Clarient Reports Strong Revenue Increase for Fourth Quarter and Full-Year 2008
3. [video] Ronald Andrews, CEO of Clarient, Inc. Discusses Agreement With University of Pennsylvania School of Medicine on WallSt.nets 3-Minute Press Show
4. Clarient Names Raymond J. Land Senior Vice President and Chief Financial Officer
5. Jim Agnello to Resign as Clarient Chief Financial Officer
6. Clarient Announces Fourth Quarter and Year-End 2007 Financial Results
7. CombiMatrix and Clarient Collaborate to Market, Sell Novel Genomics-Based Test for Chronic Lymphotic Leukemia (CLL)
8. Clarient to Commercialize Novel Breast Cancer Profile
9. Clarient CEO Ron Andrews to Participate in OneMedPlace Emerging Healthcare Technologies Finance Forum
10. Oncolytics(R) Biotech Inc. Completes Patient Enrolment in U.S. Phase 2 Sarcoma Study
11. NovImmune Completes CHF 62.5 (USD 54.8) Million Equity Financing to Move Portfolio Forward and Reacquire Product Rights to Lead Antibodies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... SAN JOSE, Calif. , Aug. 20, 2014 ... UCSD highlights the transformative collaboration between the school,s ... (IoT).  As part of the Intel® Software Academic ... between computer sciences and the human body.  ... The study exhibits the work of ...
(Date:8/19/2014)... NJ (PRWEB) August 20, 2014 ... and regenerative medicine is an inadequate vascular supply. ... constructs and decellularized tissues is critical for successful ... have attempted to mitigate deficiencies in vascularization and ... adding scaffold bioactivity, optimizing scaffold design and architecture, ...
(Date:8/19/2014)... 2014 Cellgen Diagnostics ... to fund a corporate lab for its genetic-based ... development is a critical component in the move ... the implementation of personalized medicine – a more ... , Indiegogo contributions will support Cellgen’s intent to ...
(Date:8/19/2014)... Research and Markets ... "Spectroscopy Equipment and Accessories - Global Strategic ... This report analyzes the ... in US$ Thousands by the following Product ... NMR-EPR Spectrometers, Near Infrared (NIR) Spectrometers, IR ...
Breaking Biology Technology:Intel and University of San Diego Bioengineering Department Release Case Study on Health Sciences Research 2Vascularization in Tissue Engineering Highlighted at 12th New Jersey Symposium on Biomaterials Science 2Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 2Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 3Global Spectroscopy Equipment and Accessories - Strategic Business Report 2014 2
... Jan. 2 CryoLife, Inc. (NYSE: CRY ... announced today,that it is scheduled to participate in ... Sir Francis Drake Hotel in Union Square, San,Francisco., ... operating officer and,chief financial officer of CryoLife, Inc., ...
... SAN FRANCISCO, Calif., Jan. 2 Exelixis,Inc. (Nasdaq: ... president and chief executive officer, will present at the ... 10:30 p.m. ET on,Thursday, January 10, 2008., The ... the Event,Calendar page under Investors on the Exelixis website ...
... Jan. 2 The following statement was issued,today by the ... Notice is hereby given that a class action lawsuit was ... of New York on,behalf of all purchasers of the securities ... February 17, 2006 through June 13, 2007,inclusive (the "Class Period")., ...
Cached Biology Technology:Shareholder Class Action Filed Against Sanofi-Aventis by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP 2Shareholder Class Action Filed Against Sanofi-Aventis by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP 3
(Date:8/21/2014)... University (ANU) team has successfully replicated one of the ... systems powered by sunlight which could manufacture hydrogen as ... sunlight. It is an exciting prospect to use them ... said Dr Kastoori Hingorani, from the ARC Centre of ... of Biology. , Hydrogen offers potential as a zero-carbon ...
(Date:8/21/2014)... resulting in severe abdominal pain, vomiting and systemic inflammation. ... diagnosed with the disease resulting in 1000 deaths. There ... intravenous fluid and nutritional support. , Dr Jason ... the research, said "The major causes of pancreatitis include ... intake combined with a high fat diet. In fact, ...
(Date:8/20/2014)... study of 158 pregnant teenagers in Rochester, NY, nearly ... consumption of ice, cornstarch, vacuum dust, baby powder and ... study. , Moreover, such teens had significantly lower iron ... nonfood substances. , Pregnant teens, regardless of pica, are ... to iron deficiency and anemia. Low iron in pregnant ...
Breaking Biology News(10 mins):Water and sunlight the formula for sustainable fuel 2Insulin offers new hope for the treatment of acute pancreatitis 2Pica in pregnant teens linked to low iron 2
... facing the world,s marine environments. Yet in the absence of ... plastic litter enter the ocean each year. ... Emmett Center on Climate Change and the Environment and UCLA,s ... impacts of plastic marine litter and offers domestic and international ...
... PARK, Calif. , Oct. 29, 2013 /PRNewswire-iReach/ -- ... buyout capital to emerging healthcare companies, announced today that ... Pharmaceuticals, has joined the Frazier Healthcare team as a ... long and distinguished track record as an entrepreneur, executive, ...
... and clinicians were unsung heroes during the early years (19771983) ... (VTEC). In an article published today in the Canadian ... microbiologist, documents the history of this area of study, ... Canadians to the science of what many people refer to ...
Cached Biology News:UCLA report urges new global policy effort to tackle crisis of plastic litter in oceans 2UCLA report urges new global policy effort to tackle crisis of plastic litter in oceans 3Frazier Healthcare Adds Carol Gallagher to its Life Science Team 2Frazier Healthcare Adds Carol Gallagher to its Life Science Team 3Canadian discoveries pivotal to the science of toxins and illness associated with E. coli 2
... 2'-O-Methyltransferase converts Cap 0 (or Cap 0-like) ... 1 structure has been shown to increase ... 50%. This improvement is seen in Cap ... Capping System as well as those Cap ...
Form: Ready to use Applications: ELISA...
RABBIT ANTI HALOPERIDOL...
Recombinant Mouse Serpin A1/alpha-1-Antitrypsin, CF Protein Family: Coagulation, Serine Protease Regulators...
Biology Products: